| | 79781-00-3 Basic information More.. |
| Product Name: | Bulaquine | | Synonyms: | compound 80-53;1-[4,5-Dihydro-2-[[4-[(6-methoxyquinoline-8-yl)amino]pentyl]amino]furan-3-yl]ethanone;CDRI-80/53;N-[(3-Acetyl-4,5-dihydrofuran)-2-yl]-N'-(6-methoxy-8-quinolinyl)-1,4-pentanediamine;Bulaquine;2(3H)-Furanone, dihydro-3-[1-[[4-[(6-methoxy-8-quinolinyl)amino]pentyl]amino]ethylidene]-;aablaquine | | CAS: | 79781-00-3 | | MF: | C21H27N3O3 | | MW: | 369.46 | | EINECS: | | | Mol File: | 79781-00-3.mol |  |
Use
Bulaquine is a derivative of primaquine that was introduced in India in combination with
chloroquine as a treatment against malaria. The compound is prepared by condensation
of primaquine with 3-acetyl-y-butyrolactone in presence of a catalytic amount of base.
Bulaquine kills the latent tissue stage (hypnozoites) of the parasite Plasmodium vivax
accumulated in the liver and responsible for relapses. Its efficient anti-relapse activity was
demonstrated against sporozoite induced Plasmodium cynomolgi infection in rhesus
monkey. Bulaquine is safer than primaquine, the preceding candidate against malaria
relapse. Although it is stable at pH 7-8, bulaquine is hydrolyzed to primaquine under acidic
conditions.
|
|
79781-00-3
Recommend Suppliers |
1
|